Efficacy and safety of adalimumab in Chinese patients with moderate to severe plaque psoriasis: Results from a phase 3, randomized, placebo-controlled, double-blind Study - 09/05/15
Doi : 10.1016/j.jaad.2015.02.937
Le texte complet de cet article est disponible en PDF.
Jianzhong Zhang, Peking University People’s Hospital, Beijing, China; Jun Gu, Shanghai Changhai Hospital, Shanghai, China; Jie Zheng, Ruijin Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai, China; Min Zheng, Second Affiliated Hospital Zhejiang University College of Medicine, Hangzhou, China; Gang Wang, The first Affiliated Hospital of Fourth Military Medical University, Xi’an, China; Yihua Gu, AbbVie Inc, North Chicago, IL, United States; Martin Okun, AbbVie Inc, North Chicago, IL, United States
Le texte complet de cet article est disponible en PDF.| AbbVie Inc participated in the study design; study research; collection, analysis and interpretation of data; and writing, reviewing and approving of this publication. |
© 2015
Publié par Elsevier Masson SAS.
Vol 72 - N° 5S1
P. AB232 - mai 2015 Retour au numéro
Article précédent
- Effect of certolizumab pegol on dermatologic outcomes over 96 weeks in patients with psoriatic arthritis
- Efficacy and safety of an innovative aerosol foam formulation of the fixed combination calcipotriene plus betamethasone dipropionate in patients with psoriasis—the PSO-FAST study
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?